TY - JOUR
T1 - The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment
T2 - Mexico and the United States
AU - Rothschild, Michael I.
AU - Russ, Rebecca
AU - Brennan, Kathryn A.
AU - Williams, Christopher J.
AU - Berrones, David
AU - Patel, Bhavesh
AU - Martinez-Castellanos, Maria Ana
AU - Fernandes, Alcides
AU - Hubbard, G. Baker
AU - Chan, R. V.Paul
AU - Yang, Zhou
AU - Olsen, Timothy W.
N1 - Funding Information:
Funding/Support: This work was supported by an unrestricted departmental grant from Research to Prevent Blindness (New York, NY); a departmental core grant, NEI P30 EY 006360, and Financial Support: Emory Eye Center's GO-Emory, and a portion of the travel expenses were from the Emory University School of Medicine. Also, the teachers and staff at the Center for the Visually Impaired facilitated support of the interviews in Atlanta, GA and at several schools for the blind in Mexico City. Financial disclosures: Timothy W. Olsen: Genentec-Roche (site-PI on Lampalizumab study GX29176; salary support only through Emory University, no outside fees other than meeting travel as required). The following authors have no financial disclosures: Michael I. Rothschild, Rebecca Russ, Kathryn A. Brennan, Christopher J. Williams, David Berrones, Bhavesh Patel, Maria Ana Martinez-Castellanos, Alcides Fernandes, G. Baker Hubbard III, R.V. Paul Chan, and Zhou Yang. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose To describe an economic (Ec) model for estimating the impact of screening and treatment for retinopathy of prematurity (ROP). Design EcROP is a cost-effectiveness, cost-utility, and cost-benefit analysis. Methods We surveyed caregivers of 52 children at schools for the blind or pediatric eye clinics in Atlanta, Georgia and 43 in Mexico City. A decision analytic model with sensitivity analysis determined the incremental cost-effectiveness (primary outcome) and incremental monetary benefit (secondary outcome) of an ideal (100% screening) national ROP program as compared to estimates of current practice. Direct costs included screening and treatment expenditures. Indirect costs estimated lost productivity of caretaker(s) and blind individuals as determined by face-to-face surveys. Utility and effectiveness were measured in quality-adjusted life years and benefit in US dollars. EcROP includes a sensitivity analysis to assesses the incremental cost-effectiveness and societal impact of ROP screening and treatment within a country or economic region. Estimates are based on evidence-based clinical data and region-specific economic data acquired from direct field survey. Results In both Mexico and the United States, an ideal national ROP screening and treatment program was highly cost-saving. The incremental net benefit of an ideal ROP program over current practice is $5556 per child ($206 574 333 annually) and $3628 per child ($205 906 959 annually) in Mexico and the United States, respectively. Conclusion EcROP demonstrates that ROP screening and treatment is highly beneficial for quality of life, cost saving, and cost-effectiveness in the United States and Mexico. EcROP can be applied to any country or region to provide data for informed allocation of limited health care resources.
AB - Purpose To describe an economic (Ec) model for estimating the impact of screening and treatment for retinopathy of prematurity (ROP). Design EcROP is a cost-effectiveness, cost-utility, and cost-benefit analysis. Methods We surveyed caregivers of 52 children at schools for the blind or pediatric eye clinics in Atlanta, Georgia and 43 in Mexico City. A decision analytic model with sensitivity analysis determined the incremental cost-effectiveness (primary outcome) and incremental monetary benefit (secondary outcome) of an ideal (100% screening) national ROP program as compared to estimates of current practice. Direct costs included screening and treatment expenditures. Indirect costs estimated lost productivity of caretaker(s) and blind individuals as determined by face-to-face surveys. Utility and effectiveness were measured in quality-adjusted life years and benefit in US dollars. EcROP includes a sensitivity analysis to assesses the incremental cost-effectiveness and societal impact of ROP screening and treatment within a country or economic region. Estimates are based on evidence-based clinical data and region-specific economic data acquired from direct field survey. Results In both Mexico and the United States, an ideal national ROP screening and treatment program was highly cost-saving. The incremental net benefit of an ideal ROP program over current practice is $5556 per child ($206 574 333 annually) and $3628 per child ($205 906 959 annually) in Mexico and the United States, respectively. Conclusion EcROP demonstrates that ROP screening and treatment is highly beneficial for quality of life, cost saving, and cost-effectiveness in the United States and Mexico. EcROP can be applied to any country or region to provide data for informed allocation of limited health care resources.
UR - http://www.scopus.com/inward/record.url?scp=84973342007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973342007&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2016.04.014
DO - 10.1016/j.ajo.2016.04.014
M3 - Article
C2 - 27130372
AN - SCOPUS:84973342007
SN - 0002-9394
VL - 168
SP - 110
EP - 121
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -